Literature DB >> 25658617

Peripheral neuropathy associated with ipilimumab: a report of 2 cases.

Iyavut Thaipisuttikul1, Paul Chapman, Edward K Avila.   

Abstract

Ipilimumab, a monoclonal antibody targeting human cytotoxic T-lymphocyte-associated antigen 4, was approved by the FDA and European Medicines Agency for the treatment of metastatic melanoma. Immune-related adverse effects can occur with the use of this agent, but peripheral nervous system problems are rare. We report 2 cases of ipilimumab-induced polyneuropathy.

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 25658617      PMCID： PMC5628623          DOI： 10.1097/CJI.0000000000000070

Source DB:  PubMed          Journal:  J Immunother        ISSN： 1524-9557            Impact factor:   4.456


  10 in total

1.  Ipilimumab plus dacarbazine for previously untreated metastatic melanoma.

Authors:  Caroline Robert; Luc Thomas; Igor Bondarenko; Steven O'Day; Jeffrey Weber; Claus Garbe; Celeste Lebbe; Jean-François Baurain; Alessandro Testori; Jean-Jacques Grob; Neville Davidson; Jon Richards; Michele Maio; Axel Hauschild; Wilson H Miller; Pere Gascon; Michal Lotem; Kaan Harmankaya; Ramy Ibrahim; Stephen Francis; Tai-Tsang Chen; Rachel Humphrey; Axel Hoos; Jedd D Wolchok
Journal:  N Engl J Med       Date:  2011-06-05       Impact factor: 91.245

Review 2.  Update on immunologic therapy with anti-CTLA-4 antibodies in melanoma: identification of clinical and biological response patterns, immune-related adverse events, and their management.

Authors:  Katharina C Kaehler; Sarah Piel; Elisabeth Livingstone; Bastian Schilling; Axel Hauschild; Dirk Schadendorf
Journal:  Semin Oncol       Date:  2010-10       Impact factor: 4.929

3.  Anti-CTLA-4 antibody-induced Guillain-Barré syndrome in a melanoma patient.

Authors:  S Wilgenhof; B Neyns
Journal:  Ann Oncol       Date:  2011-02-28       Impact factor: 32.976

4.  Improved survival with ipilimumab in patients with metastatic melanoma.

Authors:  F Stephen Hodi; Steven J O'Day; David F McDermott; Robert W Weber; Jeffrey A Sosman; John B Haanen; Rene Gonzalez; Caroline Robert; Dirk Schadendorf; Jessica C Hassel; Wallace Akerley; Alfons J M van den Eertwegh; Jose Lutzky; Paul Lorigan; Julia M Vaubel; Gerald P Linette; David Hogg; Christian H Ottensmeier; Celeste Lebbé; Christian Peschel; Ian Quirt; Joseph I Clark; Jedd D Wolchok; Jeffrey S Weber; Jason Tian; Michael J Yellin; Geoffrey M Nichol; Axel Hoos; Walter J Urba
Journal:  N Engl J Med       Date:  2010-06-05       Impact factor: 91.245

5.  Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma.

Authors:  Bing Liao; Sheetal Shroff; Carlos Kamiya-Matsuoka; Sudhakar Tummala
Journal:  Neuro Oncol       Date:  2014-01-30       Impact factor: 12.300

6.  CTLA-4 blockade increases IFNgamma-producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients.

Authors:  Chrysoula I Liakou; Ashish Kamat; Derek Ng Tang; Hong Chen; Jingjing Sun; Patricia Troncoso; Christopher Logothetis; Padmanee Sharma
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-25       Impact factor: 11.205

7.  The co-inhibitory molecule PD-1 modulates disease severity in a model for an inherited, demyelinating neuropathy.

Authors:  Antje Kroner; Nicholas Schwab; Chi Wang Ip; Claudia Sommer; Carsten Wessig; Heinz Wiendl; Rudolf Martini
Journal:  Neurobiol Dis       Date:  2008-10-15       Impact factor: 5.996

Review 8.  Recent findings on how proinflammatory cytokines cause pain: peripheral mechanisms in inflammatory and neuropathic hyperalgesia.

Authors:  Claudia Sommer; Michaela Kress
Journal:  Neurosci Lett       Date:  2004-05-06       Impact factor: 3.046

9.  Infliximab in the treatment of anti-CTLA4 antibody (ipilimumab) induced immune-related colitis.

Authors:  David R Minor; Kevin Chin; Mohammed Kashani-Sabet
Journal:  Cancer Biother Radiopharm       Date:  2009-06       Impact factor: 3.099

10.  Preoperative CTLA-4 blockade: tolerability and immune monitoring in the setting of a presurgical clinical trial.

Authors:  Bradley C Carthon; Jedd D Wolchok; Jianda Yuan; Ashish Kamat; Derek S Ng Tang; Jingjing Sun; Geoffrey Ku; Patricia Troncoso; Christopher J Logothetis; James P Allison; Padmanee Sharma
Journal:  Clin Cancer Res       Date:  2010-05-11       Impact factor: 12.531
  10 in total
  17 in total

Review 1.  Proposed diagnostic and treatment paradigm for high-grade neurological complications of immune checkpoint inhibitors.

Authors:  Dustin Anderson; Grayson Beecher; Nabeela Nathoo; Michael Smylie; Jennifer A McCombe; John Walker; Rajive Jassal
Journal:  Neurooncol Pract       Date:  2018-10-04

Review 2.  Checkpoint Inhibitors.

Authors:  Lucie Heinzerling; Enrico N de Toni; Georg Schett; Gheorghe Hundorfean; Lisa Zimmer
Journal:  Dtsch Arztebl Int       Date:  2019-02-22       Impact factor: 5.594

3.  Electrophysiological findings in immune checkpoint inhibitor-related peripheral neuropathy.

Authors:  Xi Chen; Aya Haggiagi; Efstathia Tzatha; Lisa M DeAngelis; Bianca Santomasso
Journal:  Clin Neurophysiol       Date:  2019-05-09       Impact factor: 3.708

Review 4.  Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update.

Authors:  Hiroki Nagai; Manabu Muto
Journal:  Int J Clin Oncol       Date:  2018-03-07       Impact factor: 3.402

5.  Nivolumab-induced immune-mediated neurotoxicity in Hodgkin lymphoma.

Authors:  James Lopez; Naveen Yarlagadda; Zaid Gheith; Meera Mohan; Appalanaidu Sasapu
Journal:  Proc (Bayl Univ Med Cent)       Date:  2019-10-25

6.  Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.

Authors:  Jaydira Del Rivero; Lisa M Cordes; Joanna Klubo-Gwiezdzinska; Ravi A Madan; Lynnette K Nieman; James L Gulley
Journal:  Oncologist       Date:  2019-10-10

7.  Case Report: Encephalitis, with Brainstem Involvement, Following Checkpoint Inhibitor Therapy in Metastatic Melanoma.

Authors:  Simon Bossart; Selina Thurneysen; Elisabeth Rushing; Karl Frontzek; Henning Leske; Daniela Mihic-Probst; Hannes W Nagel; Johanna Mangana; Simone M Goldinger; Reinhard Dummer
Journal:  Oncologist       Date:  2017-05-30

Review 8.  Immune-mediated adverse events of anticytotoxic T lymphocyte-associated antigen 4 antibody therapy in metastatic melanoma.

Authors:  Shannon K Quirk; Anna K Shure; Devendra K Agrawal
Journal:  Transl Res       Date:  2015-06-11       Impact factor: 7.012

9.  Endocrine-Related Adverse Events Related to Immune Checkpoint Inhibitors: Proposed Algorithms for Management.

Authors:  Jaydira Del Rivero; Lisa M Cordes; Joanna Klubo-Gwiezdzinska; Ravi A Madan; Lynnette K Nieman; James L Gulley
Journal:  Oncologist       Date:  2019-10-10

10.  Haploinsufficiency of immune checkpoint receptor CTLA4 induces a distinct neuroinflammatory disorder.

Authors:  Matthew K Schindler; Stefania Pittaluga; Yoshimi Enose-Akahata; Helen C Su; V Koneti Rao; Amy Rump; Steven Jacobson; Irene Cortese; Daniel S Reich; Gulbu Uzel
Journal:  J Clin Invest       Date:  2020-10-01       Impact factor: 14.808
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.